A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer

By Murren John   Modiano Manuel   Kummar Shivaani   Clairmont Caroline   Egorin Merrill   Chu Edward   Sznol Mario  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 123-135

Springer Publishing Company

Access to resources Recommend Favorite

A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer

By Shin Sang   Jeung Hei-Cheul   Ahn Joong   Rha Sun   Roh Jae   Park Kyung   Kim Dal-Hyun   Kim Chin   Chung Hyun  

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 650-658

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

By Okamoto Isamu   Miyazaki Masaki   Morinaga Ryotaro   Kaneda Hiroyasu   Ueda Shinya   Hasegawa Yoshikazu   Satoh Taroh   Kawada Akira   Fukuoka Masahiro   Fukino Koichi   Tanigawa Takahiko   Nakagawa Kazuhiko  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 844-853

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer

By Argiris Athanassios   Kut Victoria   Luong Lynn   Avram Michael  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 203-212

Springer Publishing Company

Access to resources Recommend Favorite

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer

By Chi Kim   Chia Stephen   Dixon Ross   Newman Michael   Wacher Vince   Sikic Branimir   Gelmon Karen  

Investigational New Drugs, Vol. 23, Iss. 4, 2005-08 ,pp. : 311-315

Springer Publishing Company

Access to resources Recommend Favorite